Literature DB >> 2197152

Prospects for specific immunotherapy in myasthenia gravis.

L Steinman1, R Mantegazza.   

Abstract

Myasthenia gravis is an autoimmune disease resulting from a breakdown in T and B cell tolerance to acetylcholine receptor (AChR). Autoantibodies to AChR mediate the disease. Recent advances in experimental immunotherapy of autoimmune disease provide several possibilities for specific intervention in this well-characterized condition.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2197152     DOI： 10.1096/fasebj.4.10.2197152

Source DB:  PubMed          Journal:  FASEB J        ISSN： 0892-6638            Impact factor:   5.191


  7 in total

Review 1.  Antigen specific immunotherapy of multiple sclerosis.

Authors:  L Steinman; P Conlon
Journal:  J Clin Immunol       Date:  2001-03       Impact factor: 8.317

2.  Autoimmune disease and the nervous system.

Authors:  L Steinman
Journal:  West J Med       Date:  1992-06

3.  'Split tolerance' induction by intrathymic injection of acetylcholine receptor in a rat model of autoimmune myasthenia gravis; implications for the design of specific immunotherapies.

Authors:  I Ohtsuru; H Matsuo; T Fukudome; A Suenaga; M Tsujihata; S Nagataki
Journal:  Clin Exp Immunol       Date:  1995-12       Impact factor: 4.330

4.  Immunomodulation in the treatment of multiple sclerosis and amyotrophic lateral sclerosis: a model for autoimmune disorders.

Authors:  K Alonso; R Medenica
Journal:  J Natl Med Assoc       Date:  1995-08       Impact factor: 1.798

5.  Analysis of T cell receptor repertoire of muscle-infiltrating T lymphocytes in polymyositis. Restricted V alpha/beta rearrangements may indicate antigen-driven selection.

Authors:  R Mantegazza; F Andreetta; P Bernasconi; F Baggi; J R Oksenberg; O Simoncini; M Mora; F Cornelio; L Steinman
Journal:  J Clin Invest       Date:  1993-06       Impact factor: 14.808

6.  Changes in peripheral blood lymphocyte subset frequencies in myasthenia gravis patients are related to immunosuppression.

Authors:  F Crosti; M Armanini; P Confalonieri; C Antozzi; R Mantegazza
Journal:  J Neurol       Date:  1994-02       Impact factor: 4.849

7.  Plasmapheresis combined with interferon: an effective therapy for multiple sclerosis.

Authors:  R D Medenica; S Mukerjee; K Alonso; G Lazovic; T Huschart
Journal:  J Clin Apher       Date:  1994       Impact factor: 2.821
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.